Brown Lisle Cummings Inc. Sells 6,431 Shares of Bristol-Myers Squibb (NYSE:BMY)

Brown Lisle Cummings Inc. decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 27.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 16,884 shares of the biopharmaceutical company’s stock after selling 6,431 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Bristol-Myers Squibb were worth $955,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Commonwealth Financial Services LLC raised its position in shares of Bristol-Myers Squibb by 15.1% in the 4th quarter. Commonwealth Financial Services LLC now owns 6,909 shares of the biopharmaceutical company’s stock worth $391,000 after acquiring an additional 904 shares in the last quarter. Calamos Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 2.5% in the fourth quarter. Calamos Wealth Management LLC now owns 11,123 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 270 shares in the last quarter. Trust Point Inc. raised its holdings in Bristol-Myers Squibb by 1.9% in the fourth quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company’s stock worth $533,000 after purchasing an additional 172 shares in the last quarter. Childress Capital Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 17.6% in the 4th quarter. Childress Capital Advisors LLC now owns 7,018 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 1,051 shares in the last quarter. Finally, F&V Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.9% in the 4th quarter. F&V Capital Management LLC now owns 172,158 shares of the biopharmaceutical company’s stock valued at $9,737,000 after buying an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $60.03 on Tuesday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The company has a fifty day moving average of $57.60 and a 200 day moving average of $53.34.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a $0.62 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.13%. Bristol-Myers Squibb’s dividend payout ratio is presently -69.08%.

Analysts Set New Price Targets

BMY has been the subject of a number of analyst reports. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the company from $63.00 to $70.00 in a report on Monday, December 16th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $73.00 in a research note on Tuesday, November 12th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Finally, UBS Group boosted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $56.60.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.